Monographie - Foscarnet sodium - Stabilis 4.0

Ultimele actualizari :
28/04/2024

Antiviral

Foscarnet sodium

Injectabil

Stabilitatea in solutie

Stabilitatea in amestec

Factorii care influenteaza stabilitatea

Compatibilitate

Microunde

Bibliografie

Pdf

Formula chimica

Denumirea comerciala

Denumirea comerciala

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Foscarnet	Argentina, Chilli, SUA
Foscarvir	Japonia
Foscavir	Australia, Austria, Belgia, Elvetia, Franta, Germania, Grecia, Italia, Luxemburg, Marea Britanie, Noua Zeelandă, Olanda, Spania, SUA, Suedia, Ungaria

Bibliografie

Injectabil

Bibliografie : Foscarnet sodium

	Tip	Publicare
2	Ziar	Woods K, Steinmann W, Bruns L, Neels JT. Stability of foscarnet in 0.9% sodium chloride injection. Am J Hosp Pharm 1994 ; 51: 88-90.
36	Ziar	Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC. Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods. Am J Health-Syst Pharm 1995 ; 52: 2423-2426.
64	Ziar	DiStefano JE, Outman WR. Additional data on visual compatibility of foscarnet sodium with morphine sulfate. Am J Hosp Pharm 1992 ; 49: 1672.
73	Ziar	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
75	Ziar	Mathew M, Das Gupta V, Bethea C. Stability of foscarnet sodium in 5% dextrose and 0.9% sodium chloride injections. J Clin Pharm Ther 1994 ; 19: 35-36.
132	Ziar	Najari Z, Rusho WJ. Compatibility of commonly used bone marrow transplant drugs during Y-site delivery. Am J Health-Syst Pharm 1997 ; 54: 181-184.
246	Ziar	McDonald C, Boddy M, Garas G. The stability of foscarnet in the presence of potassium. Aust J Hosp Pharm 1996 ; 26: 560-561.
496	Ziar	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
604	Laborator	Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998
1135	Ziar	Baltz JK, Kennedy P, Minor JR, Gallelli J. Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1990 ; 47: 2075-2077.
2262	Ziar	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3595	Laborator	Aciclovir - Summary of Product Characteristics Hospira 2009
3662	Laborator	Foscavir (Foscarnet®) - Summary of Product Characteristics Clinigen 2014
3728	Ziar	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3883	Laborator	Ceftazidime - Résumé des caractéristiques du produit Arrow 2016
4319	Ziar	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.

Mentions Légales